Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET study of etelcalcetide-based treatment strategies for secondary hyperparathyroidism in maintenance hemodialysis
jRCTs041180108Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label trial of etelcalcetide, calcitriol and calcium carbonate in secondary hyperparathyroidism (SHPT) and chronic kidney disease-mineral and bone disorder (CKD-MBD) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Primary efficacy endpoint. Started May 2018; status: completed.
02
Drugs
etelcalcetidecalcitriolcalcium carbonate
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease-mineral and bone disorder (CKD-MBD)
Beyond the preview
Go deeper on jRCTs041180108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180108.